Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4268MR)

This product GTTS-WQ4268MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4268MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4611MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ7268MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ5831MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ2903MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ14051MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ13114MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ14172MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6128MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA COR-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW